Our province has launched the application process for five reward policies related to biomedical and pharmaceutical industries.

This report informs that the Provincial Department of Industry and Information Technology recently launched the application process for five biopharmaceutical-related reward policies to support the R&D innovation and conversion application of new drugs and high-end medical devices for the year 2026. The policy provides a tiered reward system for the entire chain of biopharmaceutical R&D, conversion, and industrial supporting, with the maximum individual reward reaching 15 million yuan. The aim is to promote the high-quality development of the biomanufacturing industry in the province with substantial financial support, accelerating the creation of an innovative hub for the biopharmaceutical industry.

Among them, the “Support Policy for R&D Innovation of New Drugs and High-End Medical Devices” offers tiered support based on product categories and experimental progress stages. For new drugs and high-end medical devices entering clinical trials, the maximum support is 8 million yuan for Phase I, 10 million yuan for Phase II, and 15 million yuan for Phase III clinical trials. A single innovative drug completing the entire cycle of clinical trials will be rewarded up to 15 million yuan; the “Support Policy for Conversion Application of New Drugs and High-End Medical Devices” focuses on the implementation of results, providing a one-time reward for new drugs and high-end medical device products produced and sold in our province, with a maximum of 15 million yuan for innovative drugs of Category I and 3 million yuan for Category III medical devices; the “Support Policy for Secondary Development of Major Traditional Chinese Medicine Varieties” sets tiered rewards based on the additional sales revenue generated from secondary development of major traditional Chinese medicine varieties, awarding 3 million yuan, 5 million yuan, and 10 million yuan for additional sales revenues of 50 million yuan, 100 million yuan, and over 300 million yuan compared to the previous year, respectively; the “Support Policy for Centralized Bulk Purchasing of Drugs and Medical Devices” encourages enterprises to actively participate in national and inter-provincial alliance centralized purchasing and exclusive variety negotiations, granting the winning varieties a maximum reward of 5% of the total procurement amount for that year, up to 5 million yuan; the “Support Policy for Promotion of Biomanufacturing Pilot Platform Services” provides a maximum subsidy of 5 million yuan, which is 20% of the annual service amount for provincial enterprises provided by established pilot platforms, with an additional 50% increase for funds from platforms selected by the Ministry of Industry and Information Technology.

According to reports, our province will ensure the accurate distribution of reward funds through a standardized process involving third-party reviews and public announcements, fully leveraging the policy incentive effects to continuously empower the high-quality development of Longjiang’s biopharmaceutical and biomanufacturing industries.